Investing.com - Gracell Biotechnologies (NASDAQ: GRCL) reported second quarter EPS of $-0.06, $0.01 better than the analyst estimate of $-0.07. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Gracell Biotechnologies's stock price closed at $3.84. It is up 76.96% in the last 3 months and up 14.50% in the last 12 months.
Gracell Biotechnologies saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Gracell Biotechnologies's stock price’s past reactions to earnings here.
According to InvestingPro, Gracell Biotechnologies's Financial Health score is "weak performance".
Check out Gracell Biotechnologies's recent earnings performance, and Gracell Biotechnologies's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar